{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:22Z","timestamp":1790687482100,"version":"4.1.0"},"reference-count":221,"publisher":"Portland Press Ltd.","issue":"24","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,15]]},"abstract":"<jats:p>The majority of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and tumour suppressive genes, which make them a new class of targets for drug development in cancer. Although microRNAs (miRNAs) are the most studied regulatory ncRNAs to date, and miRNA-targeted therapeutics have already reached clinical development, including the mimics of the tumour suppressive miRNAs miR-34 and miR-16, which reached phase I clinical trials for the treatment of liver cancer and mesothelioma, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognised. Here, we describe obstacles and advances in the development of ncRNA therapeutics and provide the comprehensive overview of the ncRNA chemistry and delivery technologies. Furthermore, we summarise recent knowledge on the biological functions of miRNAs and their involvement in carcinogenesis, and discuss the strategies of their therapeutic manipulation in cancer. We review also the emerging insights into the role of lncRNAs and their potential as targets for novel treatment paradigms. Finally, we provide the up-to-date summary of clinical trials involving miRNAs and future directions in the development of ncRNA therapeutics.<\/jats:p>","DOI":"10.1042\/bcj20170079","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T01:20:16Z","timestamp":1513300816000},"page":"4219-4251","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["Therapeutic targeting of non-coding RNAs in cancer"],"prefix":"10.1042","volume":"474","author":[{"given":"Ondrej","family":"Slaby","sequence":"first","affiliation":[{"name":"Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Kamenice 5, Brno 625 00, Czech Republic"},{"name":"Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Laga","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"2021112216483032900_BCJ-2017-0079CC1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/embo-reports\/kve230","article-title":"Non-coding RNAs: the architects of eukaryotic complexity","volume":"2","author":"Mattick","year":"2001","journal-title":"EMBO Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","author":"ENCODE Project Consortium","year":"2012","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1479-5876-10-103","article-title":"Novel classes of non-coding RNAs and cancer","volume":"10","author":"Sana","year":"2012","journal-title":"J. Transl. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrd4018","article-title":"Targeting long non-coding RNA to therapeutically upregulate gene expression","volume":"12","author":"Wahlestedt","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC6","first-page":"210","article-title":"Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model","volume":"9","author":"Reich","year":"2003","journal-title":"Mol. Vis."},{"key":"2021112216483032900_BCJ-2017-0079CC7","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am. J. Pathol."},{"key":"2021112216483032900_BCJ-2017-0079CC8","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1128\/AAC.00014-09","article-title":"RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy","volume":"53","author":"Alvarez","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"2021112216483032900_BCJ-2017-0079CC9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ymthe.2004.05.004","article-title":"A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs","volume":"10","author":"Hagstrom","year":"2004","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4155\/tde-2016-0049","article-title":"Delivery of nucleic acids for cancer gene therapy: overcoming extra- and intra-cellular barriers","volume":"7","author":"McErlean","year":"2016","journal-title":"Ther. Deliv."},{"key":"2021112216483032900_BCJ-2017-0079CC12","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/micc.12228","article-title":"A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects","volume":"23","author":"Maeda","year":"2016","journal-title":"Microcirculation"},{"key":"2021112216483032900_BCJ-2017-0079CC15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jconrel.2012.06.029","article-title":"HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity","volume":"164","author":"Etrych","year":"2012","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","article-title":"Non-coding RNAs as drug targets","volume":"16","author":"Matsui","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-61779-188-8_8","article-title":"Antibody targeted siRNA delivery","volume":"764","author":"Toloue","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021112216483032900_BCJ-2017-0079CC23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41598-017-00966-3","article-title":"Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer","volume":"7","author":"\u00d6ze\u015f","year":"2017","journal-title":"Sci. Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/ph9040069","article-title":"Aptamer-mediated targeted delivery of therapeutics: an update","volume":"9","author":"Catuogno","year":"2016","journal-title":"Pharmaceuticals"},{"key":"2021112216483032900_BCJ-2017-0079CC26","doi-asserted-by":"publisher","first-page":"20832","DOI":"10.1038\/srep20832","article-title":"Impact of different cell penetrating peptides on the efficacy of antisense therapeutics for targeting intracellular pathogens","volume":"6","author":"Abushahba","year":"2016","journal-title":"Sci. Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/iub.1257","article-title":"Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies","volume":"66","author":"de Figueiredo","year":"2014","journal-title":"IUBMB Life"},{"key":"2021112216483032900_BCJ-2017-0079CC28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"2021112216483032900_BCJ-2017-0079CC29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/sj.gt.3300717","article-title":"Polyethylenimine-based intravenous delivery of transgenes to mouse lung","volume":"5","author":"Goula","year":"1998","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC30","first-page":"102","article-title":"Physicochemical and pharmacokinetic characteristics of cationic liposomes","volume":"61","author":"Yeeprae","year":"2006","journal-title":"Pharmazie"},{"key":"2021112216483032900_BCJ-2017-0079CC31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2015.05.003","article-title":"A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA","volume":"365","author":"Zhang","year":"2015","journal-title":"Cancer Lett."},{"key":"2021112216483032900_BCJ-2017-0079CC33","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1016\/j.biomaterials.2014.02.016","article-title":"siRNA delivery from triblock copolymer micelles with spatially-ordered compartments of PEG shell, siRNA-loaded intermediate layer, and hydrophobic core","volume":"35","author":"Kim","year":"2014","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1152\/physrev.1997.77.3.759","article-title":"Endocytosis","volume":"77","author":"Mukherjee","year":"1997","journal-title":"Physiol. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1083\/jcb.95.2.676","article-title":"Weak bases and ionophores rapidly and reversibly raise the Ph of endocytic vesicles in cultured mouse fibroblasts","volume":"95","author":"Maxfield","year":"1982","journal-title":"J. Cell Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC36","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/nar\/gkv060","article-title":"High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC37","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1093\/nar\/gkv942","article-title":"Guanabenz (Wytensin\u2122) selectively enhances uptake and efficacy of hydrophobically modified siRNAs","volume":"43","author":"Osborn","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res. Dev."},{"key":"2021112216483032900_BCJ-2017-0079CC39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/ard.1991.1.11","article-title":"Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos","volume":"1","author":"Dagle","year":"1991","journal-title":"Antisense Res. Dev."},{"key":"2021112216483032900_BCJ-2017-0079CC40","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.172.11.6545","article-title":"Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3","volume":"172","author":"Kariko","year":"2004","journal-title":"J. Immunol."},{"key":"2021112216483032900_BCJ-2017-0079CC41","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"2021112216483032900_BCJ-2017-0079CC42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0092-8674(02)71133-1","article-title":"Double-stranded RNA as a template for gene silencing","volume":"101","author":"Bass","year":"2000","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC43","first-page":"531","article-title":"In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue","volume":"6","author":"Iversen","year":"1991","journal-title":"Anticancer Drug Des."},{"key":"2021112216483032900_BCJ-2017-0079CC44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2021112216483032900_BCJ-2017-0079CC46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cmdc.200900444","article-title":"Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook","volume":"5","author":"Shukla","year":"2010","journal-title":"ChemMedChem"},{"key":"2021112216483032900_BCJ-2017-0079CC47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10059-009-0134-8","article-title":"A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides","volume":"28","author":"Oh","year":"2009","journal-title":"Mol. Cells"},{"key":"2021112216483032900_BCJ-2017-0079CC49","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/nbt.3091","article-title":"Taking charge of siRNA delivery","volume":"32","author":"Khvorova","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC50","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1371\/journal.pbio.0020098","article-title":"Sequence-specific inhibition of small RNA function","volume":"2","author":"Hutv\u00e1gner","year":"2004","journal-title":"PLoS Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC51","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1261\/rna.5235104","article-title":"Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing","volume":"10","author":"Meister","year":"2004","journal-title":"RNA"},{"key":"2021112216483032900_BCJ-2017-0079CC52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ymeth.2007.11.001","article-title":"Inhibition of microRNA with antisense oligonucleotides","volume":"44","author":"Esau","year":"2008","journal-title":"Methods"},{"key":"2021112216483032900_BCJ-2017-0079CC53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"2021112216483032900_BCJ-2017-0079CC54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/jm00059a007","article-title":"Uniformly modified 2\u2032-deoxy-2\u2032-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets","volume":"36","author":"Kawasaki","year":"1993","journal-title":"J. Med. Chem."},{"key":"2021112216483032900_BCJ-2017-0079CC55","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elm\u00e9n","year":"2008","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC56","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-05-0137","article-title":"MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells","volume":"65","author":"Chan","year":"2005","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.786","article-title":"Silencing of microRNA families by seed-targeting tiny LNAs","volume":"43","author":"Obad","year":"2011","journal-title":"Nat. Genet."},{"key":"2021112216483032900_BCJ-2017-0079CC58","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC59","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.coph.2010.06.007","article-title":"Viral vector-mediated RNA interference","volume":"10","author":"Couto","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021112216483032900_BCJ-2017-0079CC61","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/mt.2016.143","article-title":"Viral and synthetic RNA vector technologies and applications","volume":"24","author":"Schott","year":"2016","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC62","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00109-012-0985-x","article-title":"Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model","volume":"91","author":"Lou","year":"2013","journal-title":"J. Mol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC63","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/sj.onc.1206733","article-title":"Use of adeno-associated viral vector for delivery of small interfering RNA","volume":"22","author":"Tomar","year":"2003","journal-title":"Oncogene"},{"key":"2021112216483032900_BCJ-2017-0079CC64","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/mt.2013.35","article-title":"Targeting miR-21 for the therapy of pancreatic cancer","volume":"21","author":"Sicard","year":"2013","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC65","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s13346-016-0352-5","article-title":"Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy","volume":"7","author":"Mishra","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"2021112216483032900_BCJ-2017-0079CC66","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.biotechadv.2017.03.002","article-title":"Nanocarriers for microRNA delivery in cancer medicine","volume":"35","author":"Fernandez-Pi\u00f1eiro","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"2021112216483032900_BCJ-2017-0079CC67","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2174\/1381612821666150531164540","article-title":"Lipid-based nanocarriers for RNA delivery","volume":"21","author":"Xue","year":"2015","journal-title":"Curr. Pharm. Design"},{"key":"2021112216483032900_BCJ-2017-0079CC68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v28.i4.20","article-title":"Lipid nanocarriers: influence of lipids on product development and pharmacokinetics","volume":"28","author":"Pathak","year":"2011","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"2021112216483032900_BCJ-2017-0079CC69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymeth.2003.11.023","article-title":"Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications","volume":"33","author":"Dalby","year":"2004","journal-title":"Methods"},{"key":"2021112216483032900_BCJ-2017-0079CC70","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/dvdy.20873","article-title":"Optimized cationic lipid-based gene delivery reagents for use in developing vertebrate embryos","volume":"235","author":"deCastro","year":"2006","journal-title":"Dev. Dyn."},{"key":"2021112216483032900_BCJ-2017-0079CC71","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/sj.gt.3302778","article-title":"RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC72","first-page":"289","article-title":"Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives","volume":"2","author":"Uner","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"2021112216483032900_BCJ-2017-0079CC73","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2014.11.010","article-title":"Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system","volume":"197","author":"Zhang","year":"2015","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC74","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jconrel.2013.09.027","article-title":"Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2008.08.014","article-title":"Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS","volume":"132","author":"Cardoso","year":"2008","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC76","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1021\/la001779t","article-title":"Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers","volume":"17","author":"Dautzenberg","year":"2001","journal-title":"Langmuir"},{"key":"2021112216483032900_BCJ-2017-0079CC77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0168-3659(02)00045-7","article-title":"Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations","volume":"81","author":"Reschel","year":"2002","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC78","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jgm.1431","article-title":"Polyethylenimine\/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab","volume":"12","author":"H\u00f6bel","year":"2010","journal-title":"J. Gene Med."},{"key":"2021112216483032900_BCJ-2017-0079CC79","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.bmc.2010.04.031","article-title":"Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier","volume":"18","author":"Kang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"2021112216483032900_BCJ-2017-0079CC80","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","article-title":"MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma","volume":"71","author":"Ibrahim","year":"2011","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC81","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.actbio.2015.07.020","article-title":"miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy","volume":"25","author":"Gao","year":"2015","journal-title":"Acta Biomater."},{"key":"2021112216483032900_BCJ-2017-0079CC82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jps.21079","article-title":"Dendrimers as drug carriers: applications in different routes of drug administration","volume":"97","author":"Cheng","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"2021112216483032900_BCJ-2017-0079CC83","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.drudis.2014.12.012","article-title":"Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery","volume":"20","author":"Kesharwani","year":"2015","journal-title":"Drug Discov. Today"},{"key":"2021112216483032900_BCJ-2017-0079CC84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nmat4497","article-title":"Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment","volume":"15","author":"Conde","year":"2016","journal-title":"Nat. Mater."},{"key":"2021112216483032900_BCJ-2017-0079CC85","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/app.30868","article-title":"Suppression of breast cancer cells in vitro by polyamidoamine-dendrimer-mediated 5-fluorouracil chemotherapy combined with antisense micro-RNA 21 gene therapy","volume":"114","author":"Mei","year":"2009","journal-title":"J. Appl. Polym. Sci."},{"key":"2021112216483032900_BCJ-2017-0079CC86","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.biomaterials.2006.11.004","article-title":"The influence of polymeric properties on chitosan\/siRNA nanoparticle formulation and gene silencing","volume":"28","author":"Liu","year":"2007","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC87","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ymthe.2006.04.010","article-title":"RNA interference in vitro and in vivo using a novel chitosan\/siRNA nanoparticle system","volume":"14","author":"Howard","year":"2006","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC88","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1016\/j.biomaterials.2014.02.006","article-title":"Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer","volume":"35","author":"Deng","year":"2014","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC89","doi-asserted-by":"publisher","first-page":"13567","DOI":"10.1038\/srep13567","article-title":"Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells","volume":"5","author":"Santos-Carballal","year":"2015","journal-title":"Sci. Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC90","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.biomaterials.2008.07.036","article-title":"Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery","volume":"29","author":"Sun","year":"2008","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC91","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.biomaterials.2011.01.006","article-title":"A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy","volume":"32","author":"Mao","year":"2011","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC92","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.nano.2015.09.014","article-title":"Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy","volume":"12","author":"Wang","year":"2016","journal-title":"Nanomedicine"},{"key":"2021112216483032900_BCJ-2017-0079CC93","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1021\/mp500852s","article-title":"Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells","volume":"12","author":"Devulapally","year":"2015","journal-title":"Mol. Pharm."},{"key":"2021112216483032900_BCJ-2017-0079CC94","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jconrel.2012.01.014","article-title":"Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial\u2013mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma","volume":"159","author":"Chiou","year":"2012","journal-title":"J. Control. Release"},{"key":"2021112216483032900_BCJ-2017-0079CC95","doi-asserted-by":"publisher","first-page":"7971","DOI":"10.1166\/jnn.2015.11233","article-title":"Simultaneous drug and gene delivery from the biodegradable poly(\u03b5-caprolactone) nanofibers for the treatment of liver cancer","volume":"15","author":"Che","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC96","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nmeth761","article-title":"Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing","volume":"2","author":"Cai","year":"2005","journal-title":"Nat. Methods"},{"key":"2021112216483032900_BCJ-2017-0079CC97","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1002\/anie.200460437","article-title":"Functionalized carbon nanotubes for plasmid DNA gene delivery","volume":"43","author":"Pantarotto","year":"2004","journal-title":"Angew. Chem. Int. Ed."},{"key":"2021112216483032900_BCJ-2017-0079CC98","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/anie.200604295","article-title":"siRNA delivery into human T cells and primary cells with carbon-nanotube transporters","volume":"46","author":"Liu","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"key":"2021112216483032900_BCJ-2017-0079CC99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijpharm.2011.02.009","article-title":"SiRNA delivery with functionalized carbon nanotubes","volume":"416","author":"Varkouhi","year":"2011","journal-title":"Int. J. Pharm."},{"key":"2021112216483032900_BCJ-2017-0079CC100","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1586\/ecp.09.39","article-title":"Superparamagnetic iron oxide nanoparticle \u2018theranostics\u2019 for multimodality tumor imaging, gene delivery, targeted drug and prodrug delivery","volume":"3","author":"Yu","year":"2010","journal-title":"Expert Rev. Clin. Pharm."},{"key":"2021112216483032900_BCJ-2017-0079CC101","first-page":"311","article-title":"Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy","volume":"3","author":"Peng","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"2021112216483032900_BCJ-2017-0079CC102","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nm1486","article-title":"In vivo imaging of siRNA delivery and silencing in tumors","volume":"13","author":"Medarova","year":"2007","journal-title":"Nat. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC103","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1002\/anie.200805998","article-title":"All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery","volume":"48","author":"Lee","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"2021112216483032900_BCJ-2017-0079CC104","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.addr.2008.03.016","article-title":"Gold nanoparticles in delivery applications","volume":"60","author":"Ghosh","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC105","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s11095-011-0554-y","article-title":"Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles","volume":"29","author":"Kong","year":"2012","journal-title":"Pharm. Res."},{"key":"2021112216483032900_BCJ-2017-0079CC106","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jgm.2810","article-title":"Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells","volume":"16","author":"Ekin","year":"2014","journal-title":"J. Gene Med."},{"key":"2021112216483032900_BCJ-2017-0079CC107","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.biomaterials.2012.10.023","article-title":"A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells","volume":"34","author":"Ghosh","year":"2013","journal-title":"Biomaterials"},{"key":"2021112216483032900_BCJ-2017-0079CC108","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpharm.2016.05.027","article-title":"Bioconjugated gold nanoparticles enhance cellular uptake: a proof of concept study for siRNA delivery in prostate cancer cells","volume":"509","author":"Guo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"2021112216483032900_BCJ-2017-0079CC109","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1039\/C1CS15237H","article-title":"The golden age: gold nanoparticles for biomedicine","volume":"41","author":"Dreaden","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC110","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1021\/la010530o","article-title":"Evidence for bilayer assembly of cationic surfactants on the surface of gold nanorods","volume":"17","author":"Nikoobakht","year":"2001","journal-title":"Langmuir"},{"key":"2021112216483032900_BCJ-2017-0079CC111","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/smll.200700378","article-title":"Size-dependent cytotoxicity of gold nanoparticles","volume":"3","author":"Pan","year":"2007","journal-title":"Small"},{"key":"2021112216483032900_BCJ-2017-0079CC112","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1021\/bc060367e","article-title":"Targeted quantum dot conjugates for siRNA delivery","volume":"18","author":"Derfus","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"2021112216483032900_BCJ-2017-0079CC113","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.addr.2008.03.015","article-title":"Bioconjugated quantum dots for in vivo molecular and cellular imaging","volume":"60","author":"Smith","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC114","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.1021\/ja800086u","article-title":"Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging","volume":"130","author":"Yezhelyev","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"2021112216483032900_BCJ-2017-0079CC115","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC116","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC117","doi-asserted-by":"publisher","first-page":"D154","DOI":"10.1093\/nar\/gkm952","article-title":"miRBase: tools for microRNA genomics","volume":"36","author":"Griffiths-Jones","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC118","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC119","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC120","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"Krek","year":"2005","journal-title":"Nat. Genet."},{"key":"2021112216483032900_BCJ-2017-0079CC121","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC122","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","article-title":"Many roads to maturity: microRNA biogenesis pathways and their regulation","volume":"11","author":"Winter","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC123","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC124","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216483032900_BCJ-2017-0079CC125","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-06-4218","article-title":"Genetic unmasking of an epigenetically silenced microRNA in human cancer cells","volume":"67","author":"Lujambio","year":"2007","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC126","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/CS20110005","article-title":"MicroRNA profiling in cancer","volume":"121","author":"Munker","year":"2011","journal-title":"Clin. Sci."},{"key":"2021112216483032900_BCJ-2017-0079CC127","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216483032900_BCJ-2017-0079CC128","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/genes8010021","article-title":"Targeting microRNAs in cancer gene therapy","volume":"8","author":"Ji","year":"2017","journal-title":"Genes"},{"key":"2021112216483032900_BCJ-2017-0079CC129","doi-asserted-by":"publisher","first-page":"224","DOI":"10.18632\/oncotarget.129","article-title":"Is miR-29 an oncogene or tumor suppressor in CLL?","volume":"1","author":"Pekarsky","year":"2010","journal-title":"Oncotarget"},{"key":"2021112216483032900_BCJ-2017-0079CC130","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216483032900_BCJ-2017-0079CC131","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.13043","article-title":"Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia","volume":"167","author":"Lin","year":"2014","journal-title":"Br. J. Haematol."},{"key":"2021112216483032900_BCJ-2017-0079CC132","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.tcb.2008.07.007","article-title":"The let-7 family of microRNAs","volume":"18","author":"Roush","year":"2008","journal-title":"Trends Cell Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC133","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3892\/or.2014.3036","article-title":"Diverse roles of miR-29 in cancer (review)","volume":"31","author":"Jiang","year":"2014","journal-title":"Oncol. Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC134","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: a new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021112216483032900_BCJ-2017-0079CC135","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/imm.12227","article-title":"Role of miR-155 in the regulation of lymphocyte immune function and disease","volume":"142","author":"Seddiki","year":"2014","journal-title":"Immunology"},{"key":"2021112216483032900_BCJ-2017-0079CC136","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/cdd.2013.125","article-title":"The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease","volume":"20","author":"Mogilyansky","year":"2013","journal-title":"Cell Death Differ."},{"key":"2021112216483032900_BCJ-2017-0079CC137","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ddr.21257","article-title":"The role of miR-21 in cancer","volume":"76","author":"Pfeffer","year":"2015","journal-title":"Drug Dev. Res."},{"key":"2021112216483032900_BCJ-2017-0079CC138","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1582-4934.2008.00556.x","article-title":"miR-21: a small multi-faceted RNA","volume":"13","author":"Krichevsky","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC139","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13059-014-0445-8","article-title":"MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use","volume":"15","author":"Nana-Sinkam","year":"2014","journal-title":"Genome Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC140","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216483032900_BCJ-2017-0079CC141","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"van Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC142","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"2021112216483032900_BCJ-2017-0079CC143","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/nar\/gkm024","article-title":"Specificity, duplex degradation and subcellular localization of antagomirs","volume":"35","author":"Kr\u00fctzfeldt","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC144","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1618","article-title":"Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model","volume":"28","author":"Ma","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC145","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/nm.2227","article-title":"miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma","volume":"16","author":"Swarbrick","year":"2010","journal-title":"Nat. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC146","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC147","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1021\/cr050266u","article-title":"Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA)","volume":"107","author":"Kaur","year":"2007","journal-title":"Chem. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC148","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood-2012-02-410647","article-title":"LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"2021112216483032900_BCJ-2017-0079CC149","doi-asserted-by":"publisher","first-page":"e90337","DOI":"10.1371\/journal.pone.0090337","article-title":"Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy","volume":"9","author":"Bernardo","year":"2014","journal-title":"PLoS ONE"},{"key":"2021112216483032900_BCJ-2017-0079CC150","doi-asserted-by":"publisher","first-page":"e29275","DOI":"10.1371\/journal.pone.0029275","article-title":"Rapid generation of microRNA sponges for microRNA inhibition","volume":"7","author":"Kluiver","year":"2012","journal-title":"PLoS ONE"},{"key":"2021112216483032900_BCJ-2017-0079CC151","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/gt.2011.79","article-title":"Developing therapeutic microRNAs for cancer","volume":"18","author":"Bader","year":"2011","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC152","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1007\/s11095-011-0548-9","article-title":"MicroRNA replacement therapy for cancer","volume":"28","author":"Henry","year":"2011","journal-title":"Pharm. Res."},{"key":"2021112216483032900_BCJ-2017-0079CC153","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1261\/rna.789808","article-title":"Strand-specific 5\u2032-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity","volume":"14","author":"Chen","year":"2008","journal-title":"RNA"},{"key":"2021112216483032900_BCJ-2017-0079CC154","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"key":"2021112216483032900_BCJ-2017-0079CC155","doi-asserted-by":"publisher","first-page":"e38129","DOI":"10.1371\/journal.pone.0038129","article-title":"Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles","volume":"7","author":"Tivnan","year":"2012","journal-title":"PLoS ONE"},{"key":"2021112216483032900_BCJ-2017-0079CC156","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC157","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol. Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC158","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-10-0655","article-title":"Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34","volume":"70","author":"Wiggins","year":"2010","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC159","doi-asserted-by":"publisher","first-page":"e67581","DOI":"10.1371\/journal.pone.0067581","article-title":"MiR-34a\/c-dependent PDGFR-\u03b1\/\u03b2 downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer","volume":"8","author":"Garofalo","year":"2013","journal-title":"PLoS ONE"},{"key":"2021112216483032900_BCJ-2017-0079CC160","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1080\/15384101.2014.1003008","article-title":"Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation","volume":"14","author":"Stahlhut","year":"2015","journal-title":"Cell Cycle"},{"key":"2021112216483032900_BCJ-2017-0079CC161","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/17425240902992894","article-title":"Controlled delivery of antisense oligonucleotides: a brief review of current strategies","volume":"6","author":"Zhao","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"2021112216483032900_BCJ-2017-0079CC162","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.addr.2012.09.011","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"64","author":"Jain","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021112216483032900_BCJ-2017-0079CC163","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/ng.915","article-title":"Germline deletion of the miR-17 approximately 92 cluster causes skeletal and growth defects in humans","volume":"43","author":"de Pontual","year":"2011","journal-title":"Nat. Genet."},{"key":"2021112216483032900_BCJ-2017-0079CC164","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2008.10.006","article-title":"NF-\u03baB\u2013YY1\u2013miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma","volume":"14","author":"Wang","year":"2008","journal-title":"Cancer Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC165","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","article-title":"microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma","volume":"115","author":"Zhao","year":"2010","journal-title":"Blood"},{"key":"2021112216483032900_BCJ-2017-0079CC166","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1182\/blood-2009-03-211938","article-title":"MicroRNA 29b functions in acute myeloid leukemia","volume":"114","author":"Garzon","year":"2009","journal-title":"Blood"},{"key":"2021112216483032900_BCJ-2017-0079CC167","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"2021112216483032900_BCJ-2017-0079CC168","doi-asserted-by":"publisher","first-page":"E2110","DOI":"10.1073\/pnas.1209414109","article-title":"MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response","volume":"109","author":"Fabbri","year":"2012","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216483032900_BCJ-2017-0079CC169","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/gt.2011.50","article-title":"MicroRNA therapeutics","volume":"18","author":"Broderick","year":"2011","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC170","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.gt.3302694","article-title":"Prospects of RNA interference therapy for cancer","volume":"13","author":"Pai","year":"2006","journal-title":"Gene Ther."},{"key":"2021112216483032900_BCJ-2017-0079CC171","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"2021112216483032900_BCJ-2017-0079CC172","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","article-title":"Inhibition of coagulation by a phosphorothioate oligonucleotide","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"2021112216483032900_BCJ-2017-0079CC173","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC174","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/emboj.2011.2","article-title":"Small RNA-mediated regulation of iPS cell generation","volume":"30","author":"Li","year":"2011","journal-title":"EMBO J."},{"key":"2021112216483032900_BCJ-2017-0079CC175","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1073\/pnas.0904715106","article-title":"Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression","volume":"106","author":"Khalil","year":"2009","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216483032900_BCJ-2017-0079CC176","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2011.12.047","article-title":"Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells","volume":"142","author":"Almeida","year":"2012","journal-title":"Gastroenterology"},{"key":"2021112216483032900_BCJ-2017-0079CC177","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","volume":"111","author":"van der Ree","year":"2014","journal-title":"Antiviral Res."},{"key":"2021112216483032900_BCJ-2017-0079CC178","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC179","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC180","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"suppl 15","key":"2021112216483032900_BCJ-2017-0079CC181","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2016.34.15_suppl.2508","article-title":"MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: final dose-escalation results from a first-in-human phase I trial of microRNA therapy","volume":"34","author":"Hong","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2021112216483032900_BCJ-2017-0079CC182","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"2021112216483032900_BCJ-2017-0079CC183","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/349038a0","article-title":"A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome","volume":"349","author":"Brown","year":"1991","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC184","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","article-title":"The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression","volume":"22","author":"Derrien","year":"2012","journal-title":"Genome Res."},{"key":"2021112216483032900_BCJ-2017-0079CC185","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/bies.20544","article-title":"The relationship between non-protein-coding DNA and eukaryotic complexity","volume":"29","author":"Taft","year":"2007","journal-title":"BioEssays"},{"key":"2021112216483032900_BCJ-2017-0079CC186","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1126\/science.1112009","article-title":"Antisense transcription in the mammalian transcriptome","volume":"309","author":"Katayama","year":"2005","journal-title":"Science"},{"key":"2021112216483032900_BCJ-2017-0079CC187","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrm2738","article-title":"Regulatory roles of natural antisense transcripts","volume":"10","author":"Faghihi","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC188","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ccr.2007.07.027","article-title":"Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas","volume":"12","author":"Calin","year":"2007","journal-title":"Cancer Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC189","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC190","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature12986","article-title":"The multilayered complexity of ceRNA crosstalk and competition","volume":"505","author":"Tay","year":"2014","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC191","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/jcmm.12952","article-title":"Pseudogenes regulate parental gene expression via ceRNA network","volume":"21","author":"An","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC192","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol. Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC193","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/0008-5472.CAN-10-4379","article-title":"Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression","volume":"71","author":"Aguilo","year":"2011","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC194","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature07672","article-title":"Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals","volume":"458","author":"Guttman","year":"2009","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC195","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10398","article-title":"lincRNAs act in the circuitry controlling pluripotency and differentiation","volume":"477","author":"Guttman","year":"2011","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC196","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature11661","article-title":"Control of somatic tissue differentiation by the long non-coding RNA TINCR","volume":"493","author":"Kretz","year":"2013","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC197","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/jcmm.12956","article-title":"HULC: an oncogenic long non-coding RNA in human cancer","volume":"21","author":"Yu","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC198","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1093\/nar\/gkq285","article-title":"CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"2021112216483032900_BCJ-2017-0079CC199","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1007\/s13277-014-2523-7","article-title":"Long noncoding RNA HOTAIR involvement in cancer","volume":"35","author":"Wu","year":"2014","journal-title":"Tumour Biol."},{"key":"2021112216483032900_BCJ-2017-0079CC200","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC201","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1126\/science.1098119","article-title":"Ultraconserved elements in the human genome","volume":"304","author":"Bejerano","year":"2004","journal-title":"Science"},{"key":"2021112216483032900_BCJ-2017-0079CC202","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.1088328","article-title":"Scanning human gene deserts for long-range enhancers","volume":"302","author":"Nobrega","year":"2003","journal-title":"Science"},{"key":"2021112216483032900_BCJ-2017-0079CC203","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-9-441","article-title":"Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma","volume":"9","author":"Scaruffi","year":"2009","journal-title":"BMC Cancer"},{"key":"2021112216483032900_BCJ-2017-0079CC204","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000336479","article-title":"Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer","volume":"82","author":"Sana","year":"2012","journal-title":"Oncology"},{"key":"2021112216483032900_BCJ-2017-0079CC205","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/nature09144","article-title":"A coding-independent function of gene and pseudogene mRNAs regulates tumour biology","volume":"465","author":"Poliseno","year":"2010","journal-title":"Nature"},{"key":"2021112216483032900_BCJ-2017-0079CC206","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/mc.22594","article-title":"PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma","volume":"56","author":"Gao","year":"2017","journal-title":"Mol. Carcinog."},{"key":"2021112216483032900_BCJ-2017-0079CC207","doi-asserted-by":"publisher","first-page":"e008653","DOI":"10.1136\/bmjopen-2015-008653","article-title":"Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis","volume":"5","author":"Tian","year":"2015","journal-title":"BMJ Open"},{"key":"2021112216483032900_BCJ-2017-0079CC208","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1038\/sj.onc.1206928","article-title":"MALAT-1, a novel noncoding RNA and thymosin \u03b24 predict metastasis and survival in early-stage non-small cell lung cancer","volume":"22","author":"Ji","year":"2003","journal-title":"Oncogene"},{"key":"2021112216483032900_BCJ-2017-0079CC209","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","article-title":"The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation","volume":"39","author":"Tripathi","year":"2010","journal-title":"Mol. Cell"},{"key":"2021112216483032900_BCJ-2017-0079CC210","doi-asserted-by":"publisher","first-page":"e1003201","DOI":"10.1371\/journal.pgen.1003201","article-title":"Human disease-associated genetic variation impacts large intergenic non-coding RNA expression","volume":"9","author":"Kumar","year":"2013","journal-title":"PLoS Genet."},{"issue":"suppl 1","key":"2021112216483032900_BCJ-2017-0079CC211","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1755-8794-6-S1-S7","article-title":"Potential roles of microRNAs in regulating long intergenic noncoding RNAs","volume":"6","author":"Juan","year":"2013","journal-title":"BMC Med. Genomics"},{"key":"2021112216483032900_BCJ-2017-0079CC212","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2158","article-title":"Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation","volume":"30","author":"Modarresi","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2021112216483032900_BCJ-2017-0079CC213","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.celrep.2013.12.015","article-title":"Regulation of the apolipoprotein gene cluster by a long noncoding RNA","volume":"6","author":"Halley","year":"2014","journal-title":"Cell Rep."},{"key":"2021112216483032900_BCJ-2017-0079CC214","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/onc.2012.193","article-title":"HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer","volume":"32","author":"Kim","year":"2013","journal-title":"Oncogene"},{"key":"2021112216483032900_BCJ-2017-0079CC215","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1053\/j.gastro.2006.08.026","article-title":"Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA","volume":"132","author":"Panzitt","year":"2007","journal-title":"Gastroenterology"},{"key":"2021112216483032900_BCJ-2017-0079CC216","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.bbrc.2016.08.065","article-title":"The HIF-2\u03b1-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy","volume":"478","author":"Yuan","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112216483032900_BCJ-2017-0079CC217","doi-asserted-by":"publisher","first-page":"622","DOI":"10.18632\/oncotarget.5807","article-title":"Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer","volume":"7","author":"Thorenoor","year":"2016","journal-title":"Oncotarget"},{"key":"2021112216483032900_BCJ-2017-0079CC218","first-page":"73","article-title":"Exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases","volume":"90","author":"Prabhakar","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"2021112216483032900_BCJ-2017-0079CC219","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","article-title":"The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells","volume":"73","author":"Gutschner","year":"2013","journal-title":"Cancer Res."},{"key":"2021112216483032900_BCJ-2017-0079CC220","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1006\/bbrc.1998.9241","article-title":"Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target","volume":"249","author":"Phylactou","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112216483032900_BCJ-2017-0079CC221","first-page":"2094","article-title":"Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors","volume":"6","author":"Pavco","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/24\/4219\/693172\/bcj-2017-0079c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/24\/4219\/693172\/bcj-2017-0079c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:31:58Z","timestamp":1637623918000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/474\/24\/4219\/49657\/Therapeutic-targeting-of-non-coding-RNAs-in-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":221,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,12,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20170079","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}